Navigation Links
Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
Date:1/31/2011

160;Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.  

(i)  National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures

(ii)  International Agency for Research on Cancer, GLOBOCAN 2002 database


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... DUBLIN , Nov. 27, 2014 ... of the "Global Palmitic Acid Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The Global Palmitic Acid ... on the current state of the global palmitic acid ... of the industry including definitions, classifications, applications and industry ...
(Date:11/26/2014)... November 26, 2014 Publicis Healthcare Communications ... announced the organization has won a total of 20 ... Health LifeBrands was honored with a Silver Award and ... received eight Awards of Excellence. , The Annual ... advertising and promotion. The Awards provide a forum for ...
(Date:11/26/2014)... , Nov. 26, 2014 The announced ... indicate the company is looking to expand in non-healthcare ... sales.  The healthcare market research firm says that  Siemens ... Kalorama Information,s biennial survey of the IVD market , ... any change in its composition would likely affect IVD ...
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... care consulting firm with offices in Bethesda, MD and Pittsburgh, ... January 2012: , Karen Gerlach, PhD, MPH, to ... Vice President, Program Operations and Over-the-Counter Switch , Mitch ... to President , John Pinney, to Chief Executive Officer ...
... 2012 Aethlon Medical, Inc. (OTCBB: ... devices to address infectious disease, cancer and other ... an Extracorporeal Therapy Scientific Advisory Board to guide ... therapies developed from the Aethlon ADAPT™ system.  Aethlon ...
... Jan. 23, 2012 Novus International Inc., a leading ... and Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced the selection of ... the two companies, strategic collaboration to advance ...
Cached Biology Technology:PinneyAssociates Announces Senior Staff Promotions 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 2First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 3First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 4First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 5
(Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
(Date:11/4/2014)... OXFORD, England , November 4, 2014 ... expansion and vertical market growth   Fuel3D ... it has closed a funding round totaling $6.4 million (£4 ... (£1.6 million) funding secured earlier this year and paves the ... product in 2015. The funding round was led ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... provide statin drugs free of charge so that customers can ... Imperial College London suggest in a new study published this ... in the blood. A wealth of trial data has proven ... attack risk. In a paper published in the Sunday ...
... Mount Sinai School of Medicine, New York, has been ... receive a 2010 ICAAC Young Investigator Award. Sponsored ... an early career scientist for research excellence in microbiology ... postdoctoral training in Molecular Biology at Harvard University in ...
... 250 scientists, engineers, government advisers and groups concerned ... from August 15-20, 2010 to consider the impact ... University of Maryland is co-sponsoring the conference, The ... ), which is co-organized by University of Maryland ...
Cached Biology News:Free statins with fast food could neutralize heart risk, scientists say 2University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life 2University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life 3
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
Biology Products: